MabVax Therapeutics And Telik Sign Definitive Merger Agreement

May 12, 2014 MabVax Therapeutics, Inc., a privately held cancer immunotherapy company and Telik, Inc., a clinical stage oncology drug development company have entered into a definitive merger agreement.  Upon closing of the transaction, MabVax and Telik will be combined into a publicly traded company focused on the development of proprietary immunotherapy-based products to diagnose and treat cancer.  Under the …